-DOCSTART- -X- O
Emerging -X- _ O
viruses -X- _ O
are -X- _ O
a -X- _ O
major -X- _ O
threat -X- _ O
to -X- _ O
human -X- _ O
health. -X- _ O
Recent -X- _ O
outbreaks -X- _ O
have -X- _ O
emphasized -X- _ O
the -X- _ O
urgent -X- _ O
need -X- _ O
for -X- _ O
new -X- _ O
antiviral -X- _ O
treatments. -X- _ O
For -X- _ O
several -X- _ O
pathogenic -X- _ O
viruses -X- _ O
, -X- _ O
considerable -X- _ O
efforts -X- _ O
have -X- _ O
focused -X- _ O
on -X- _ O
vaccine -X- _ O
development. -X- _ O
However -X- _ O
, -X- _ O
during -X- _ O
epidemics -X- _ O
infected -X- _ O
individuals -X- _ O
need -X- _ O
to -X- _ O
be -X- _ O
treated -X- _ O
urgently. -X- _ O
High-throughput -X- _ O
screening -X- _ O
of -X- _ O
clinically -X- _ O
tested -X- _ O
compounds -X- _ O
provides -X- _ O
a -X- _ O
rapid -X- _ O
means -X- _ O
to -X- _ O
identify -X- _ O
undiscovered -X- _ O
, -X- _ O
antiviral -X- _ O
functions -X- _ O
for -X- _ O
well-characterized -X- _ O
therapeutics. -X- _ O
Repurposed -X- _ B-I
drugs -X- _ I-I
can -X- _ O
bypass -X- _ B-o
part -X- _ I-o
of -X- _ I-o
the -X- _ I-o
early -X- _ I-o
cost -X- _ I-o
and -X- _ I-o
time -X- _ I-o
needed -X- _ I-o
for -X- _ I-o
validation -X- _ I-o
and -X- _ I-o
authorization. -X- _ I-o
In -X- _ O
this -X- _ O
review -X- _ O
we -X- _ O
describe -X- _ O
recent -X- _ O
efforts -X- _ O
to -X- _ O
find -X- _ O
broad -X- _ O
spectrum -X- _ O
antivirals -X- _ O
through -X- _ O
drug -X- _ B-I
repurposing. -X- _ I-I
We -X- _ O
have -X- _ O
chosen -X- _ O
several -X- _ O
candidates -X- _ O
and -X- _ O
propose -X- _ O
strategies -X- _ O
to -X- _ O
understand -X- _ O
their -X- _ O
mechanism -X- _ O
of -X- _ O
action -X- _ O
and -X- _ O
to -X- _ O
determine -X- _ O
how -X- _ O
resistance -X- _ O
to -X- _ O
antivirals -X- _ O
develops -X- _ O
in -X- _ O
infected -X- _ O
cells -X- _ O
. -X- _ O

